| pubmed-article:7389430 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C0006434 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C0007546 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C0040341 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C0043241 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:7389430 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:7389430 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:7389430 | pubmed:dateCreated | 1980-9-28 | lld:pubmed |
| pubmed-article:7389430 | pubmed:abstractText | 20 patients with serious infections were treated with cefazolin and tobramycin for 9--64 days. Minimal inhibitory concentration (MIC) values and minimal bactericidal concentration (MBC) values were determined for each of the 112 clinical bacterial isolates. The median cefazolin MIC/MBC was 1.56/12.5 micrograms/ml, and the median tobramycin MIC/MBC was 6.25/25.0 micrograms/ml for all organisms studied. Median cefazolin doses of 49.0 mg/kg/day gave median peak/trough serum levels of 43.0/11.0 micrograms/ml. Median tobramycin doses of 4.3 mg/kg/day gave median peak/trough serum levels of 5.0/1.4 micrograms/ml. Checkerboard studies revealed synergy with 65% of strains. Bacteriologic and clinical success was obtained in 17 of 20 patients. | lld:pubmed |
| pubmed-article:7389430 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7389430 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7389430 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7389430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7389430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7389430 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7389430 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7389430 | pubmed:issn | 0009-3157 | lld:pubmed |
| pubmed-article:7389430 | pubmed:author | pubmed-author:FransonT RTR | lld:pubmed |
| pubmed-article:7389430 | pubmed:author | pubmed-author:EdwardsL DLD | lld:pubmed |
| pubmed-article:7389430 | pubmed:author | pubmed-author:CollinsR FRF | lld:pubmed |
| pubmed-article:7389430 | pubmed:author | pubmed-author:RootT ETE | lld:pubmed |
| pubmed-article:7389430 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7389430 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:7389430 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7389430 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7389430 | pubmed:pagination | 384-96 | lld:pubmed |
| pubmed-article:7389430 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:meshHeading | pubmed-meshheading:7389430-... | lld:pubmed |
| pubmed-article:7389430 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:7389430 | pubmed:articleTitle | Treatment of twelve burn wound infections and eight other serious infections with cefazolin and tobramycin: in vitro and in vivo evaluation. | lld:pubmed |
| pubmed-article:7389430 | pubmed:publicationType | Journal Article | lld:pubmed |
